Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RNF19A

Gene summary for RNF19A

Gene summary.

Gene information	Species	Human
	Gene symbol	RNF19A
	Gene ID	25897
	Gene name	ring finger protein 19A, RBR E3 ubiquitin protein ligase
	Gene Alias	RNF19
	Cytomap	8q22.2
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	Q9NV58

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
25897	RNF19A	GSM4909287	Human	Breast	IDC	2.73e-13	5.79e-01	0.2057
25897	RNF19A	GSM4909290	Human	Breast	IDC	1.09e-11	4.67e-01	0.2096
25897	RNF19A	GSM4909298	Human	Breast	IDC	1.87e-18	4.96e-01	0.1551
25897	RNF19A	GSM4909311	Human	Breast	IDC	3.32e-09	-1.52e-01	0.1534
25897	RNF19A	GSM4909317	Human	Breast	IDC	3.00e-10	3.94e-01	0.1355
25897	RNF19A	GSM4909319	Human	Breast	IDC	6.97e-12	-8.05e-02	0.1563
25897	RNF19A	GSM4909321	Human	Breast	IDC	2.92e-03	-1.25e-01	0.1559
25897	RNF19A	M1	Human	Breast	IDC	1.36e-36	1.00e+00	0.1577
25897	RNF19A	NCCBC6	Human	Breast	DCIS	4.22e-02	4.85e-01	0.2095
25897	RNF19A	P1	Human	Breast	IDC	5.14e-12	5.12e-01	0.1527
25897	RNF19A	DCIS2	Human	Breast	DCIS	9.80e-45	2.91e-01	0.0085
25897	RNF19A	CA_HPV_1	Human	Cervix	CC	2.00e-02	2.41e-02	0.0264
25897	RNF19A	CCI_2	Human	Cervix	CC	3.27e-05	1.65e+00	0.5249
25897	RNF19A	CCI_3	Human	Cervix	CC	3.25e-03	6.43e-01	0.516
25897	RNF19A	HTA11_3410_2000001011	Human	Colorectum	AD	1.43e-10	-4.45e-01	0.0155
25897	RNF19A	HTA11_3361_2000001011	Human	Colorectum	AD	8.96e-04	-5.19e-01	-0.1207
25897	RNF19A	HTA11_83_2000001011	Human	Colorectum	SER	3.43e-03	-3.93e-01	-0.1526
25897	RNF19A	HTA11_696_2000001011	Human	Colorectum	AD	7.30e-16	-5.07e-01	-0.1464
25897	RNF19A	HTA11_866_2000001011	Human	Colorectum	AD	1.32e-03	-3.02e-01	-0.1001
25897	RNF19A	HTA11_5212_2000001011	Human	Colorectum	AD	1.02e-02	-5.95e-01	-0.2061

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00991701	Colorectum	CRC	postsynaptic modulation of chemical synaptic transmission	6/2078	15/18723	3.82e-03	3.19e-02	6
GO:004217616	Endometrium	AEH	regulation of protein catabolic process	100/2100	391/18723	9.58e-16	3.59e-13	100
GO:190336216	Endometrium	AEH	regulation of cellular protein catabolic process	70/2100	255/18723	5.40e-13	1.25e-10	70
GO:001049816	Endometrium	AEH	proteasomal protein catabolic process	108/2100	490/18723	2.73e-12	4.67e-10	108
GO:000989616	Endometrium	AEH	positive regulation of catabolic process	104/2100	492/18723	9.38e-11	1.10e-08	104
GO:190305016	Endometrium	AEH	regulation of proteolysis involved in cellular protein catabolic process	58/2100	221/18723	3.58e-10	3.77e-08	58
GO:003133116	Endometrium	AEH	positive regulation of cellular catabolic process	91/2100	427/18723	9.15e-10	8.31e-08	91
GO:004316116	Endometrium	AEH	proteasome-mediated ubiquitin-dependent protein catabolic process	88/2100	412/18723	1.54e-09	1.36e-07	88
GO:004586216	Endometrium	AEH	positive regulation of proteolysis	81/2100	372/18723	2.72e-09	2.06e-07	81
GO:200005816	Endometrium	AEH	regulation of ubiquitin-dependent protein catabolic process	45/2100	164/18723	7.49e-09	5.22e-07	45
GO:006113616	Endometrium	AEH	regulation of proteasomal protein catabolic process	49/2100	187/18723	8.64e-09	5.96e-07	49
GO:004573216	Endometrium	AEH	positive regulation of protein catabolic process	56/2100	231/18723	1.60e-08	9.99e-07	56
GO:003243416	Endometrium	AEH	regulation of proteasomal ubiquitin-dependent protein catabolic process	37/2100	134/18723	1.32e-07	6.04e-06	37
GO:190336416	Endometrium	AEH	positive regulation of cellular protein catabolic process	40/2100	155/18723	3.03e-07	1.31e-05	40
GO:19030529	Endometrium	AEH	positive regulation of proteolysis involved in cellular protein catabolic process	32/2100	133/18723	2.12e-05	4.15e-04	32
GO:200006016	Endometrium	AEH	positive regulation of ubiquitin-dependent protein catabolic process	27/2100	107/18723	3.74e-05	6.50e-04	27
GO:003243610	Endometrium	AEH	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	23/2100	90/18723	1.11e-04	1.58e-03	23
GO:19018009	Endometrium	AEH	positive regulation of proteasomal protein catabolic process	27/2100	114/18723	1.21e-04	1.67e-03	27
GO:00002098	Endometrium	AEH	protein polyubiquitination	44/2100	236/18723	4.83e-04	4.97e-03	44
GO:004217617	Endometrium	EEC	regulation of protein catabolic process	103/2168	391/18723	3.54e-16	1.52e-13	103

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RNF19A

SNV

Missense_Mutation

c.254N>C

p.Asn85Thr

p.N85T

Q9NV58

protein_coding

tolerated_low_confidence(0.37)

benign(0)

TCGA-A2-A0EX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

RNF19A

SNV

Missense_Mutation

novel

c.1550N>T

p.Ala517Val

p.A517V

Q9NV58

protein_coding

tolerated(0.39)

benign(0.012)

TCGA-A2-A3XY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

RNF19A

SNV

Missense_Mutation

novel

c.1554N>G

p.Ser518Arg

p.S518R

Q9NV58

protein_coding

deleterious(0.04)

possibly_damaging(0.723)

TCGA-A8-A07B-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF19A

SNV

Missense_Mutation

novel

c.95T>G

p.Met32Arg

p.M32R

Q9NV58

protein_coding

deleterious_low_confidence(0.01)

benign(0.202)

TCGA-A8-A09A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

RNF19A

SNV

Missense_Mutation

c.1756N>G

p.Thr586Ala

p.T586A

Q9NV58

protein_coding

tolerated(0.39)

benign(0.251)

TCGA-AO-A0J9-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

RNF19A

SNV

Missense_Mutation

c.1515G>C

p.Glu505Asp

p.E505D

Q9NV58

protein_coding

tolerated(0.23)

benign(0.005)

TCGA-AO-A0JD-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

RNF19A

SNV

Missense_Mutation

c.1771N>A

p.Ala591Thr

p.A591T

Q9NV58

protein_coding

deleterious(0.04)

benign(0.368)

TCGA-GM-A2DB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxol

RNF19A

insertion

Nonsense_Mutation

novel

c.2024_2025insGTTACCCAAACTGCTTCCTGTTCAGAAGTTTCACAGTTGAATCATAT

p.Ser675ArgfsTer14

p.S675Rfs*14

Q9NV58

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

RNF19A

insertion

Nonsense_Mutation

novel

c.686_687insCACTTGCCGAAAGTGTTTTTAAGTGCATTTCTATCCCAGA

p.Ala230ThrfsTer7

p.A230Tfs*7

Q9NV58

protein_coding

TCGA-A8-A090-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF19A

SNV

Missense_Mutation

c.1586G>A

p.Arg529Gln

p.R529Q

Q9NV58

protein_coding

tolerated(0.2)

possibly_damaging(0.652)

TCGA-C5-A1BK-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1